Medindia

X

Cynosure Names Paul Cardarelli Vice President of Business Development

Thursday, September 17, 2009 General News J E 4
Advertisement




WESTFORD, Mass., Sept. 16 Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced the appointment of Paul B. Cardarelli as Vice President of Business Development, a new position for the company. He will initially be responsible for the day-to-day management of Cynosure's funded cooperative agreement with Unilever Ltd. to develop and commercialize aesthetic devices for the home use personal care market.



"Over his nearly 20 years in the aesthetic industry, Paul has demonstrated success in worldwide product marketing, business development and organizational leadership that will directly benefit Cynosure, particularly as we expand into the home use segment of the market," said Michael Davin, the company's president and chief executive officer. "With Paul's technical background and strong experience in the development of aesthetic devices, he is well suited to lead our effort into emerging markets. While his initial focus will primarily be managing our relationship with Unilever, we are also excited about his ability to drive other initiatives."



Before joining Cynosure, Cardarelli worked as European Zone Director for Ulthera Corporation, where he was responsible for the development and implementation of a new ultrasound technology for the aesthetic market in the European Union. Cardarelli's role at Ulthera included engaging key opinion leaders to cultivate clinical sites, expanding sales channels, and implementing sales and marketing training programs.



Prior to that he spent 16 years at aesthetic laser company Candela Corporation, where he served in senior marketing roles from 1999 to 2007. As vice president of marketing, his accomplishments included developing strategies that significantly expanded the company's business with non-core physicians, implementing successful global marketing campaigns, and evaluating potential product and technology acquisitions for product line extensions. Previously, Cardarelli worked as associate product manager for Candela's Urology and Cryosurgery division and later as group product manager for the company's Dermatology and Plastic Surgery division.



About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit www.cynosure.com.



Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the global economic recession and its effects on the aesthetic laser industry, Cynosure's history of operating losses, its reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which are filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.



Contact Scott Solomon Vice President Sharon Merrill Associates, Inc. 617-542-5300 cyno@investorrelations.com

SOURCE Cynosure, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Video: Ulthera(TM) Receives First-Ever FDA Cleara...
S
Haemonetics Signs Comprehensive Agreement with Blo...